Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report

BAUFRETON, Christophe, et al.

Abstract
Drug-induced valvular heart disease (DI-VHD) remains an under-recognized entity.

Reference
BAUFRETON, Christophe, et al. Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report. Medicine (Baltimore), 2017, vol. 96, no. 2, p. e4985

PMID: 28079786
DOI: 10.1097/MD.0000000000004985

Available at:
http://archive-ouverte.unige.ch/unige:93757

Disclaimer: layout of this document may differ from the published version.
Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery
A case report

Christophe Baufreton, MD, PhD, Patrick Bruneval, MD, PhD, Marie-Christine Rousselet, MD, PhD,
Pierre-Vladimir Ennezat, MD, PhD, Olivier Fouquet, MD, Raphael Giraud, MD, PhD,
Carlo Banfi, MD, PhD, FCCP

Abstract
Rationale: Drug-induced valvular heart disease (DI-VHD) remains an under-recognized entity.
Patient concerns: This report describes a heart valve replacement which was complicated by intractable systemic pulmonary arterial hypertension in a 61-year-old female with severe restrictive mitral and aortic disease. The diagnosis of valvular disease was preceded by a history of unexplained respiratory distress. The patient had been exposed to benfluorex for 6.5 years.
Diagnoses: The diagnostic procedure documented specific drug-induced valvular fibrosis.
Interventions: Surgical mitral and aortic valve replacement was performed.
Outcomes: Heart valve replacement was postoperatively complicated by unanticipated disproportionate pulmonary hypertension. This issue was fatal despite intensive care including prolonged extracorporeal life support.
Lessons: Benfluorex is a fenfluramine derivative which has been marketed between 1976 and 2009. Although norfenfluramine is the common active and toxic metabolite of all fenfluramine derivatives, the valvular and pulmonary arterial toxicity of benfluorex was much less known than that of fenfluramine and dexfenfluramine. The vast majority of benfluorex-induced valvular heart disease remains misdiagnosed as hypothetical rheumatic fever due to similarities between both etiologies. Better recognition of DI-VHD is likely to improve patient outcome.
Abbreviation: DI-VHD = drug-induced valvular heart disease.
Keywords: cardiac surgery, fenfluramin, pulmonary hypertension, valvular heart disease

1. Introduction

Benfluorex, a fenfluramine derivative, induces restrictive drug-induced valvular heart disease (DI-VHD)[1] and seldom pulmo-
nonin demonstrated drug-induced valvular disease by demonstrating prolonged extracorporeal life support. Pathology examination administration of inotropic agents and nitric oxide as well as pressure 58mmHg) developed and the patient died despite pulmonary artery pressure 53mmHg, mean systemic arterial function. However, systemic pulmonary hypertension (mean showed normal valve prostheses and right and left ventricle (Fig. 1, panel C). Intraoperative transesophageal echocardiography showed aortic lea retraction, mitral lea sural fusion (Fig. 1, panels A, B). Due to extreme chordal tendinae mitral apparatus associated with lea retraction, mitral leaflets were fused with papillary muscles. In contrast aortic leaflets were thin with noncoronary cusp prolapse (Fig. 1, panel C). Intraoperative transesophageal echocardiography showed normal valve prostheses and right and left ventricle function. However, systemic pulmonary hypertension (mean pulmonary artery pressure 53mmHg, mean systemic arterial pressure 58mmHg) developed and the patient died despite administration of inotropic agents and nitric oxide as well as prolonged extracorporeal life support. Pathology examination demonstrated drug-induced valvular disease by demonstrating noninflammatory endocardial fibrosis on both mitral (Fig. 1, panels D, E) and aortic valves (Fig. 1, panels F, G).

3. Discussion
Since World War II, the incidence of rheumatic fever as a main cause of restrictive valvular disease has declined significantly and has been progressively replaced in Western countries by other etiologies including degenerative, genetic, radiation-induced, or drug-induced valve disease.

Activation of the 5-HT2B receptor by norfenfluramine (the active metabolite of benfluorex as well as fenfluramine and dextfenfluramine) is thought to be the main mechanism of development of DI-VHD. 5-HT2B receptors activation produces valvular endocardial fibrosis with thickened and retracted leaflets associated with chordae tendinae thickening, fusion, and retraction of the subvalvular mitral apparatus. Pathology analysis shows that the valve architecture is well preserved without inflammation or neovascularization. In contrast rheumatic heart disease leads to scarring fibrosis, inflammatory damage with disruption of the valve layers and with neoangiogenesis including thick-wall vessels. Finally anorexigen exposure produces distinctive valvular lesions from other valvular disease etiologies. Calcifications may noteworthy be observed in both etiologies.

In clinical practice DI-VHD often produces severe symptoms despite mild or moderate regurgitation due to restrictive valve opening and thereby pulmonary hypertension. The restrictive mitral valve disease may be dynamic with exercise or loading conditions; repeated mitral regurgitation worsening directly impacts on left atrial pressure and thereby pulmonary artery pressures. Of note commissural fusions thought to be specific to rheumatic fever may also be found in benfluorex-induced VHD and further aggravate leaflet opening restriction and symptoms. Dextfenfluramine-related endocardial cardiac fibrosis producing restrictive physiology remains to be demonstrated in benfluorex treated patients. Although preoperative cardiac catheterization showed postcapillary pulmonary hypertension, the patient immediately developed systemic pulmonary hypertension following valve replacement similar to pulmonary arterial hypertension suggesting an additional precapillary component.
Interestingly in the present case, in addition to aortic valve cusp prolapse which is common finding in benfluorex-induced VHD,[9] the cusps were found to be intraoperatively normal despite pathological features of DI-VHD.

In conclusion, a history of heart failure or valve replacement related to restrictive valvular disease in a patient without history of rheumatic fever should alert the clinician of potential adverse drug effect.

Acknowledgments
The authors thank Shona Cosgrove MSc for editing assistance.

References
[1] Weill A, Païta M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010;19:1256–62.
[2] Savale L, Chaumais MC, Cotin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012;40:1164–72.
[3] Bhattacharyya S, Schapira AH, Mikhailidis DP, et al. Drug-induced fibrotic valvular heart disease. Lancet 2009;374:577–85.
[4] McDonald PC, Wilson JE, Gao M, et al. Quantitative analysis of human heart valves. Does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol 2002;11:251–62.
[5] Plurien F, Bruneval P, Jobic Y, et al. Calcifications in benfluorex-induced valve heart disease: a misknown association. Cardiology 2015;130:87–90.
[6] Malergue MC, Bruneval P, Czitrom D, et al. Fatal dynamic mitral regurgitation as a presentation of benfluorex-induced valvular heart toxicity. Int J Cardiol 2015;184:549–51.
[7] Jobic Y, Etienne Y, Bruneval P, et al. Benfluorex-induced mitral stenosis: a misknown etiology. Int J Cardiol 2014;177:174–5.
[8] Fowles RE, Cloward TV, Yowell RL. Endocardial fibrosis associated with fenfuramine-phenetermine. N Engl J Med 1998;338:1316.
[9] Ennezat PV, Bruneval P, Mariéchaux S, et al. Operative finding of aortic cusp prolapse in benfluorex-induced aortic regurgitation. Int J Cardiol 2015;186:231–2.